Amylyx Pharmaceuticals, Inc. (AMLX) Stock Score, Valuation & Financial Research

Amylyx Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AMLX

Amylyx Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 28.04. These figures are a research snapshot, not a buy or sell recommendation.

What Amylyx Pharmaceuticals, Inc. does

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Amylyx Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative and endocrine diseases. The company currently does not generate product revenue following the withdrawal of its only commercial product, RELYVRIO/ALBRIOZA, and is focused on advancing its clinical-stage pipeline, including avexitide and AMX0035.

Products and services

  • The company's pipeline includes clinical-stage candidates such as avexitide for post-bariatric hypoglycemia and AMX0035 for various neurodegenerative and endocrine conditions.

Customer types

Clinical trial participants; Healthcare providers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial supplies; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Gubra A/S — Research collaboration focused on peptide-based drug discovery and preclinical contract research services. Source
  • Breakthrough T1D — Provides funding for clinical trials investigating AMX0035 as an adjunctive therapy for insulin resistance in type 1 diabetes. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting high unmet medical needs Source

Business risks and research considerations

  • Clinical development setbacks and failure to achieve regulatory approval Source
  • Dependence on third-party collaborators and contract manufacturers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AMLX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 28.04
Market capitalization:
3.12B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -152.09M
Free cash flow:
USD -123.48M
Cash:
USD 49.33M
Total debt:
USD 5.26M
EPS:
USD -1.41

What stands out

  • Free cash flow is USD -123.48M, negative for the stored period.
  • The balance sheet shows USD 49.33M of cash versus USD 5.26M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 44.07M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AMLX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AMLX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is AMLX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for AMLX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of AMLX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research AMLX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.